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ABSTRACT
Objectives: Adiponectin, a major cytokine from adipose tissue, and high sensitivity C-reactive protein (hs-CRP), well-established markers of 
inflammation are known to be associated with increased risk of cardiovascular disorders (CVD). Therefore the objective of our study was to evaluate 
the levels of these parameters and determine their correlation with glycemia to assess the cardiovascular risks in the patients with Type 2 diabetes 
mellitus. 
Methods: This study was conducted in the Department of Biochemistry, Santosh Medical College, Ghaziabad, with 25 Type 2 diabetic patients and 25 
age and sex-matched controls. Ethical clearance from the institution and informed consent from the patients were taken before the study. Adiponectin 
was analyzed by enzyme-linked immunoadsorbent assay, and blood sugar and CRP were estimated by the kit based method. 
Results: Fasting blood sugar (FBS, 158.2±37.2) and hs-CRP (3.97±1.54) were significantly high, adiponectin was significantly low in the patients with 
diabetes compared to controls (80.52±9.72, 1.27±0.75, and 10.78±1.69, respectively, p<0.05). Adiponectin showed a negative correlation with FBS 
(r=−0.427) and hs-CRP (r=−0.336), but the correlation was significant only in case of FBS (p<0.05). hs-CRP positively correlated with FBS (r=0.568) 
and was statistically significant. 
Conclusion: The results of our study further support the role of adiponectin and hs-CRP as a predictive biomarker of CVD risks in the patients suffering from 
Type 2 diabetes.
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INTRODUCTION
Diabetes mellitus, the most common metabolic disorder featured 
with hyperglycemia [1], is an important area of concern worldwide 
due to its increasing prevalence and complications [2]. In 2011, the 
International Diabetic Federation (FDI) stated that almost 8.5% of the 
worldwide population is diabetic [2], with age group most affected 
being 20-79 years. The main reason for the epidemic of diabetes is 
the escalation of its causes [3]. Rapid sociocultural changes including 
lifestyle changes, aging, urbanization, changes in dietary habits, and 
physical inactivity are the major contributing factors [4]. Technical 
advances and modernization have made it possible to accomplish 
most of the daily activities in less time with minimum efforts using 
sophisticated instruments. Furthermore, substitution of low-calorie 
diets such as ragi with junk foods such as burger and pizzas lead to 
obesity which is one of the major predisposing factors of diabetes [5].
India is regarded as the diabetes capital as it has the highest 
prevalence of diabetes, accounting for more than 11.6% in the urban 
areas. Diabetes has been linked with excess body weight gain [6] and 
increased cardiovascular risk, where dyslipidemia and inflammation 
are the major contributing factors [7]. Several studies have reported 
lower health-related quality of life in patients with diabetes, that is 
further associated with the diabetic complications [8].
Cardiovascular disorders (CVD) are one of the major causes of 
morbidity and mortality in Type 2 diabetes [9]. C-reactive protein 
(CRP), an early biomarker of inflammation, has been shown to increase 
the risks of CVD in diabetic patients, as it is involved in the formation 
of atheromatous plaque [10]. However, it is yet to be clarified that 
whether the increase in the CRP is due to metabolic effects of obesity 
that promotes atherosclerosis or it merely signifies the inflammation 
persisting in the vessels affected in diabetes.
Several epidemiological as well as experimental studies in the past 
have shown that adiponectin, a major adipokine of adipocytes, have a 
beneficial role in glucose metabolism. It not only improves the insulin 
sensitivity but also lowers cardiovascular risks by suppressing the 
inflammatory mechanisms [11]. However, reports are conflicting 
whether the anti-inflammatory property possessed by adiponectin is 
apparent in diabetic patients or the effects of metabolic factors such 
as lipids and glycemia largely mediate them. Therefore, this study was 
planned to evaluate the relationship of adiponectin with CRP, so that 
the outcome of this study can serve as an aid in early prediction marker 
of cardiovascular complications in diabetes mellitus and improve the 
quality of living.
METHODS
It is a case–control study that included 25 healthy controls and 25 Type 
2 diabetic patients. This study was carried out in the Department of 
Biochemistry, Santosh Medical College and Hospital, Ghaziabad. This 
study was carried out after ethical approval by the Institutional Ethical 
Committee. Every participant voluntarily participated, and written 
consent was taken from them. The information of patient was collected 
in prescribed format regarding age, gender, family history of diabetes, 
medication, smoking, etc.
Inclusion criteria
• Patients with Type 2 diabetes mellitus were included in this study.
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Exclusion criteria
• Patients with asthma, chronic obstructive pulmonary disease, 
inflammations, malignancies, STDs, hepatic diseases, cardiovascular, 
renal diseases, and gout and arthritis patients with Type 1 diabetes 
mellitus were excluded from the study.
Blood samples from both controls and patients were collected, and the 
serum was separated for the analysis of parameters such as adiponectin, 
hs-CRP, and fasting blood glucose. Serum adiponectin was analyzed by 
enzyme-linked immunosorbent assay while high sensitivity CRP (hs-
CRP) and glucose were estimated by kit based methods. The data were 
recorded and analyzed statistically using Student’s t-test and Pearson’s 
correlation coefficient.
RESULTS
A total of 25 Type 2 diabetic patients were included in the study of 
which 17 (68%) were males and 8 (32%) were females (Table 1). 
25 age and sex-matched healthy controls were also included in the 
comparative study. The parameters studied in both control groups and 
diabetic groups were fasting blood sugar (FBS), serum adiponectin, 
and hs-CRP. The mean±standard deviation (SD) for serum adiponectin 
was higher in control group (10.78±1.69) than in case of diabetic group 
(5.64±1.78), and the difference of mean was statistically significant 
(p<0.05, Table 2). The mean±SD for FBS and hs-CRP was higher in the 
diabetic group (FBS-158.2±32.72 and hs-CRP-3.97±1.54) compared 
to control group (FBS-80.52±9.72 and hs-CRP-1.27±0.75), and the 
difference was statistically significant (p<0.05, Table 2).
Adiponectin was negatively correlated with FBS, and the correlation 
was statistically significant (r=−0.427, p<0.05) whereas when CRP 
was considered, it showed significant positive correlation with the FBS 
(r=0.568, p<0.05). Adiponectin was negatively correlated with CRP, 
but the correlation was not statistically significant (r=0.336, p>0.05, 
Table 3). Table 4 shows the cardiovascular risk on the basis of the level 
of hs-CRP.
DISCUSSION
In the context of present scenario, prevention of diabetes has become 
one of the major health priority issues, as it not only requires long-term 
medical care to maintain the glycemic status but also increases the 
medical expenditure due to its life-threatening complications. Hence, 
in this study, we investigated the levels of serum adiponectin and hs-
CRP in Type 2 diabetic patients and compared with that of healthy 
controls. Results of this study support the hypothesis that diabetes is 
relatively associated with decreased adiponectin and increased CRP 
levels which can further lead to the development of CVD in future. 
Adiponectin, a major cytokine from adipose tissue which has been 
shown to reduce cardiovascular risk [11], was decreased in diabetic 
patients while CRP, a well-established biomarker for prediction of CVD 
was elevated. Table 4 shows the assessment of CVD risk based on the 
levels of hs-CRP.
Adiponectin exhibits both insulin-sensitizing and anti-inflammatory 
effects, thus showing protective role by improving insulin secretion 
as well as impeding cytokine and fatty acid-mediated dysfunction of 
pancreatic β-cells [13]. Adiponectin through receptors 1 and 2 affects 
glucose metabolism [14]. It lowers blood sugar level by activating 
AMP-dependent protein kinase, which stimulates catabolism of both 
intracellular and extracellular energy sources (TAG and glucose, 
respectively) [15]. Adiponectin also lowers hepatic glucose synthesis 
by decreasing expression of the gluconeogenic enzyme [16].
Obesity is one of the major risk factors for diabetes as it is associated 
with insulin resistance that can further lead to the development of 
atherothrombotic disease in diabetic patients [17]. Through various 
experimental studies, it has been documented that there is reduced 
expression of adiponectin gene in obese subjects (which may be 
attributed to increased inflammatory cytokines and persistence of 
hypoxia in adipose tissue) or during the intake of high calorie whereas 
intake of energy within normal level does not impair expression of 
adiponectin gene and level of adiponectin in blood [18].
Thus, the exact underlying mechanism though is still to be clarified; 
it can be proposed that energy intake regulates adiponectin levels 
through the effects on adiponectin gene expression. In Type 2 diabetes, 
though there is a hyperglycemic state in the body, most of the cells 
cannot utilize glucose due to insulin resistance. Therefore, it can be 
hypothesized that hyperglycemia in diabetes mimics the increased 
calorie status of the body, that might lead to suppression of adiponectin 
gene leading to hypoadiponectinemia.
In our study too, hypoadiponectinemia was prevalent among the 
diabetic patients, and it was associated with increased cardiovascular 
risk which was determined by assessing CRP. The results of our 
study are supported by various studies conducted in the past. 
Kumuda et al. [11] and Hotta et al. [19] in their studies stated that 
hypoadiponectinemia was independently associated with the risk 
of CVD in diabetes, after consideration of other known risk factors. 
According to Mohan et al., hypoadiponectinemia is related to 
dyslipidemia which is one of the causative factors of coronary artery 
disease [20]. In a follow-up study conducted by Bahceci et al. [21], 
escalation of CRP indicated the increased the risk of a CAD. Similarly, 
in another study, it was documented that Type 2 diabetic men with 
CAD presented higher CRP levels in comparison to the diabetic 
men without CAD [22]. Statnick et al. quoted that expression of 
adiponectin gene is downregulated in obese diabetic patients than 
in non-diabetic and obese individuals [23]. Festa et al. suggested that 
people developing DM had higher baseline levels of hs-CRP than in 
controls [24], thus supporting our study.
Table 4: Assessment of cardiovascular risk according to CRP 
levels [12]
Hs‑CRP Cardiovascular risk
0 to <1 mg/L Low risk 
1 to 3 mg/L Intermediate risk 
> 3 to 10 mg/L High risk
>10 mg/L Unspecific elevation
hs-CRP: High sensitivity C-reactive protein, FBS: Fasting blood sugar, 
CRP: C-reactive protein
Table 2: Comparison of adiponectin and hs‑CRP among control 
group and diabetic group
Parameter Control Diabetic p
FBS (mg/dl) 80.52±9.72 158.2±32.72 <0.05
Adiponectin (ng/ml) 10.78±1.69 5.64±1.78 <0.05
Hs-CRP (mg/L) 1.27±0.75 3.97±1.54 <0.05
hs-CRP: High sensitivity C-reactive protein, FBS: Fasting blood sugar
Table 3: Correlation of adiponectin and hs‑CRP with fasting 
blood glucose
Parameter r p
FBS -Adiponectin −0.427 <0.05
FBS - hs-CRP 0.568 <0.05
Adiponectin-CRP −0.336 >0.05
hs-CRP: High sensitivity C-reactive protein, FBS: Fasting blood sugar
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However, some studies have shown the results contrast to our findings. 
Obot et al. demonstrated no significant difference in the levels of serum 
adiponectin among diabetic patients and control [25]. Another study of 
Ljubic et al. also reported the similar result [26]. Furthermore, a cross-
sectional study of Streja et al. elucidated no association of hs-CRP with 
the complications of diabetes [27].
In this study, we also correlated adiponectin with CRP and both of them 
with FBS. We found a negative correlation of adiponectin with FBS 
and CRP while FBS and CRP were positively correlated. Our study was 
supported by the various previous studies. Wu et al. showed a positive 
correlation of hs-CRP with HbA1C and fasting blood glucose [28]. 
Venkatesh et al. [29] described an inverse correlation between plasma 
C-reactive protein and adiponectin, as well as a linear response 
between sickness severity and plasma adiponectin. The negative 
correlation between levels of C-reactive protein with adiponectin was 
also described by Ouchi et al. [30], and Engeli et al. [31]., and Krakoff 
et al. elucidated adiponectin to be an important connection between 
inflammation, obesity, and Type 2 diabetes [32].
Studies have also shown that antidiabetic drugs (like thiazolidinones) 
act by increasing levels of adiponectin. Recently adipoRN has been 
discovered which is suggested to be a novel therapeutic target for 
the treatment of diabetes associated with obesity [16]. However, 
further studies that facilitate a better understanding of the role of 
adiponectin in the reduction of Type 2 diabetes and associated CVDs 
are necessary.
CONCLUSION
According to the observation found in this study, it can be indicated that 
Type 2 diabetes is associated with decreased adiponectin and increased 
inflammatory markers such as hs-CRP. Since both the parameters are 
an important marker for CVD, fluctuations in their level can predispose 
the patients with type 2 diabetes toward the development of CVD in 
future. Although our study is very simplified, the outcomes of this 
study can further enlighten the physicians about the adverse effects of 
diabetes and hence encourage them for early detection and prevention 
of diabetes. As some results contradictory to ours have been found 
in past researches, our findings require elaboration through further 
studies. Since our study also possesses some limitations such as small 
sample size and use of single inflammatory marker, future study with 
larger samples and more promising tool to assess cardiovascular risk 
is suggested. Furthermore, studies with much focus on mechanistic 
prospective, showing the correlation of glycemic status, dyslipidemia 
and various other inflammatory markers that can predict the 
cardiovascular risk in diabetes are indicated. Besides that, modifications 
in lifestyle, as well as researches in therapeutic approaches that can 
increase adiponectin level, may be conducted to shed light on the 
alleviation of cardiovascular risks.
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